KARD Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

24.465

Open

23.690

VWAP

23.83

Vol

272.99K

Mkt Cap

2.09B

Low

23.180

Amount

6.50M

EV/EBITDA(TTM)

Total Shares

87.67M

EV/OCF(TTM)

P/S(TTM)

Kardigan, Inc. is a clinical-stage precision therapeutics company. It is developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. Its pipeline of products includes Danicamtiv, Ataciguat and Tonlamarsen. Danicamtiv is an investigational oral cardiac atrial and ventricular myosin activator for the treatment of genetic dilated cardiomyopathy caused by pathogenic variants in myosin heavy chain 7 (MYH7) and titin, the common sarcomeric gene variants. Ataciguat is an investigational oral, once-daily soluble guanylate cyclase activator aimed at slowing the progression of calcific aortic valve stenosis in patients with moderate diseases. Tonlamarsen is an investigational liver-directed antisense oligonucleotide administered once-monthly via subcutaneous injection, targeting hepatic angiotensinogen for the management of blood pressure in acute severe hypertension post-hospitalization. Prolaio is a clinical intelligence platform.

Events Timeline

(ET)

2026-07-06

10:30:00

Bending Spoons IPO Priced at $29, Opens at $31

2026-06-30 (ET)

2026-06-30

10:00:00

Sinda, DPC Holdings, and DSC Holdings Successfully Debut in IPOs

2026-06-22 (ET)

2026-06-22

13:30:00

Kardigan Raises $400M in Initial Public Offering

2026-06-18 (ET)

2026-06-18

13:00:00

Kardiga Prices IPO at $16 per Share

2026-06-18

05:00:00

Deal Size Increased to 25M Shares, Priced at High End of $16.00

News

8.5

06-22Newsfilter

Kardigan, Inc. Successfully Closes IPO Raising $460 Million

8.5

06-21Yahoo Finance

Kardigan Stock Surges 37.5% Amid Investor Interest

8.5

06-18renaissancecapital

Kardigan's IPO Soars 37.5% on First Day, Highlighting Biotech Strength

8.5

06-18seekingalpha

Kardigan Shares Surge 15% on First Trading Day After $400M IPO

8.5

06-18Newsfilter

Kardigan Shares Rise 1.6% in Nasdaq Debut After $400 Million IPO

8.5

06-18renaissancecapital

Kardigan Raises $400 Million in IPO for Cardiovascular Therapies

0 Analyst Rating

Wall Street analysts forecast KARD stock price to rise

0 Buy

0 Hold

0 Sell

Current: 0.000

Low

Averages

High

Current: 0.000

Low

Averages

High

No data

Valuation Metrics

The current forward P/E ratio for Kardigan Inc (KARD.O) is 0.00, compared to its 5-year average forward P/E of --. For a more detailed relative valuation and DCF analysis to assess Kardigan Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

Current PE

0.00

Overvalued PE

Undervalued PE

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

Undervalued EV/EBITDA

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

Current PS

0.00

Overvalued PS

Undervalued PS

Financials

AI Analysis

Annual

Quarterly

Whales Holding KARD

Trading Trends

People Also Watch

Frequently Asked Questions

What is Kardigan Inc (KARD) stock price today?

The current price of KARD is 23.83 USD — it has increased 0.21

What is Kardigan Inc (KARD)'s business?

What is the price predicton of KARD Stock?

Wall Street analysts forecast KARD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KARD is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.